A team committed to the development of a therapeutic portfolio in hearing loss


Sensorion is a pioneering clinical-stage biotech company, dedicated to the development of innovative therapies to restore, treat and prevent within the field of hearing loss

Nawal Ouzren

CEO and Director
  • 15 years in pharmaceutical operations and strategic management
  • Formerly VP and Head, Hemophilia Franchise, Baxalta (within Shire)
  • Formerly Group Vice President, Rare Genetic Diseases, Shire

Géraldine Honnet

Chief Medical Officer
  • 20 years in clinical development and gene therapy
  • Formerly Director of Development, Genethon; Senior Clinical Manager, Transgene; Medical Director, Parexel International;
  • M.D.

Juergen Heitmann

Chief Business Officer
  • 20 years in Business Development
  • Former Head of BD at Nycomed (Takeda) and Novartis; ex-McKinsey & Company
  • Independent consultant, risk-capital and biotech strategy and development
  • PhD Physiology of the inner ear

Judith Laredo

Clinical Research Director
  • 20 years in clinical research monitoring
  • Formerly Alliance Manager Oncology and Head of Translational Research, Servier
  • PhD Pharmacology and Toxicology

Valérie Salentey

Director of Regulatory Affairs & Quality Assurance
  • Over 10 years in Regulatory Affairs and Quality Assurance in Biologics and advanced therapies
  • Formerly headed Regulatory Affairs at Cytheris, Généthon, PPD, Neovacs
  • Doctor of Pharmacy (PharmD)

Laurent Désiré

Preclinical Development Director
  • Over 15 years in pharmaceutical R&D and clinical development, especially in gene therapy and neuroscience
  • Formerly Head of Cellular and Molecular Biology unit at YposKesi, and R&D Executive Director at Diaxonhit and ExonHit
  • PhD, Biology of Aging

Christine Le Bec

Head of CMC Gene Therapy
  • 25 years in production process development for gene therapy
  • Formerly Head of CMC analytical department, Genethon
  • PhD, Biochemistry and Analytical Chemistry

Nora Yang

Chief Scientific Officer
  • 25 years in R&D management in pharmaceutical industry, academia, and the government
  • Formerly Co-Founder and CSO at Stratify; Senior roles at the NIH, Amgen and Eli Lilly
  • PhD Chemistry; MS Management

Stéphanie Filipe

Head of the Project Management Office
  • 15 years in therapeutic products development in Biotechs from bench to beside including gene and cell therapies
  • Formerly R&D Director at OTR3, Program Leader at Cellectis
  • PhD, Cellular Biology & Biochemistry

Otmane Boussif

Chief Technical Officer
  • 25 years in CMC development/implementation and in developing different biologic modalities
  • Formerly Head Cell Therapy & Viral Vectors at Novartis; Senior roles at Sanofi Pasteur, Merck-Serono and Aventis
  • Ph.D. BioPhysico-Chemistry

Nawal Ouzren

CEO and Director
  • 15 years in pharmaceutical operations and strategic management
  • Formerly VP and Head, Hemophilia Franchise, Baxalta (within Shire)
  • Formerly Group Vice President, Rare Genetic Diseases, Shire

Edwin Moses

Chairman of the Board
  • 20 years biopharma industry experience
  • Former CEO and Chair, Ablynx; former director, Evotex OAI, former CEO and Chair, Oxford Asymmetry
  • Chairman of the Board at Achilles Therapeutics, Avantium NV, LabGenius Ltd and “Operating Partner” at Keensight Capital

Khalil Barrage

Director, Representative of Invus
  • 15 years of experience in portfolio management at The Olayan Group in New York
  • Managing Director for the Invus Group in News York and Board member of Protagenic and Celtaxsys

Julien Miara

Director, Representative of Invus
  • 10 years of experience in investment, covering biotechnology among other sectors
  • Director at Invus

Cédric Moreau

Director representing Sofinnova Partners
  • 18 years of experience in investment banking and in life sciences
  • Partner in the Crossover investment team at Sofinnova Partners

John Furey

Independent Director
  • 20 years of experience as CEO and Chief Operating Officer in pharmaceutical societies
  • CEO of Imvax
  • Non Executive Director at Adaptimmune

Eric de la Fortelle

Independent Director
  • 10 years of experience as scientific researcher in biotechnology, CEO and member of several Boards
  • Venture Partner at Seventure Partners

Chahra Louafi

Permanent Representative of BPI investment
  • 20 years of experience as Investment Director
  • Investment Director at Bpifrance

Jean-François Morin

  • 7 years of experience as Investment Director
  • Investments Director for Innobio fund, at Bpifrance

Pr Christine Petit

Chair of the Scientific Advisory Board
  • Chair of Genetics and Cellular Physiology,  Professor at College de France and at Institut Pasteur (Paris)
  • Head of the Laboratory of Genetics and Physiology of Hearing  at Institut Pasteur
  • Managing Director of the French Hearing Institute
  • Member of the French and American Sciences Academies  and the American Medical Academy

Pr Alain Fischer

  • Professor at College de France
  • Former director and founding member of the Institute for Genetic Diseases (Imagine)
  • Former director of the pediatric immuno-hematology department at Necker Hospital

Dr Robert Dow

  • More than 37 years of experience in the pharmaceutical and biotech industry
  • Former Chief Medical Officer at PPD Inc.
  • Substantial experience across therapeutic areas from pre-clinical to Phase 3 development

Pr Paul Avan

  • Physicist and Medical Doctor in Biophysics
  • Head of the Center for Research and Innovation in Human Audiology at Hearing Institute (Paris)
  • Designed original objective methods of exploration of the cochlea and auditory pathways

Dr Diane Lazard

  • ENT Surgeon and former Head of Clinic at AP-HP
  • Principal Associate Investigator at the Hearing Institute (Paris)
  • Currently pursuing research on deciphering language processing variability in deafness

Dr Hernán López-Schier

  • Senior Group Leader and Research Unit Director at the Helmholtz Center in Munich
  • Currently pursuing research on fundamental sensory biology and sensory dysfunction
  • His group was the first to visualize the regeneration of mechanosensory hair cells in their natural context